"Sarcoglycans" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A family of transmembrane dystrophin-associated proteins that play a role in the membrane association of the DYSTROPHIN-ASSOCIATED PROTEIN COMPLEX.
| Descriptor ID |
D049031
|
| MeSH Number(s) |
D12.776.210.500.410.750 D12.776.543.268.750 D12.776.543.550.712
|
| Concept/Terms |
beta-Sarcoglycan- beta-Sarcoglycan
- beta Sarcoglycan
- 43-kDa Dystrophin-Associated Glycoprotein
- 43 kDa Dystrophin Associated Glycoprotein
- Dystrophin-Associated Glycoprotein, 43-kDa
- Glycoprotein, 43-kDa Dystrophin-Associated
alpha-Sarcoglycan- alpha-Sarcoglycan
- alpha Sarcoglycan
- Adhalin
- 50-kDa Dystrophin-Associated glycoprotein
- 50 kDa Dystrophin Associated glycoprotein
- Dystrophin-Associated glycoprotein, 50-kDa
- glycoprotein, 50-kDa Dystrophin-Associated
|
Below are MeSH descriptors whose meaning is more general than "Sarcoglycans".
Below are MeSH descriptors whose meaning is more specific than "Sarcoglycans".
This graph shows the total number of publications written about "Sarcoglycans" by people in this website by year, and whether "Sarcoglycans" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2006 | 1 | 0 | 1 |
| 2015 | 1 | 0 | 1 |
| 2017 | 0 | 1 | 1 |
| 2018 | 1 | 0 | 1 |
| 2019 | 0 | 1 | 1 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Sarcoglycans" by people in Profiles.
-
The extracellular matrix differentially directs myoblast motility and differentiation in distinct forms of muscular dystrophy: Dystrophic matrices alter myoblast motility. Matrix Biol. 2024 May; 129:44-58.
-
A gene-edited mouse model of limb-girdle muscular dystrophy 2C for testing exon skipping. Dis Model Mech. 2019 11 04; 13(2).
-
Efficient exon skipping of SGCG mutations mediated by phosphorodiamidate morpholino oligomers. JCI Insight. 2018 05 03; 3(9).
-
Intermittent Glucocorticoid Dosing Improves Muscle Repair and Function in Mice with Limb-Girdle Muscular Dystrophy. Am J Pathol. 2017 Nov; 187(11):2520-2535.
-
Reengineering a transmembrane protein to treat muscular dystrophy using exon skipping. J Clin Invest. 2015 Nov 02; 125(11):4186-95.
-
Myofiber-specific inhibition of TGFß signaling protects skeletal muscle from injury and dystrophic disease in mice. Hum Mol Genet. 2014 Dec 20; 23(25):6903-15.
-
Excess SMAD signaling contributes to heart and muscle dysfunction in muscular dystrophy. Hum Mol Genet. 2014 Dec 20; 23(25):6722-31.
-
P38a MAPK underlies muscular dystrophy and myofiber death through a Bax-dependent mechanism. Hum Mol Genet. 2014 Oct 15; 23(20):5452-63.
-
Deletion of periostin reduces muscular dystrophy and fibrosis in mice by modulating the transforming growth factor-ß pathway. Proc Natl Acad Sci U S A. 2012 Jul 03; 109(27):10978-83.
-
Distinct pathophysiological mechanisms of cardiomyopathy in hearts lacking dystrophin or the sarcoglycan complex. FASEB J. 2011 Sep; 25(9):3106-14.